Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B R Krause

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Biochemical and Biophysical Research Communications|July 31, 1990
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductaseM K Shaw, R S Newton, D R Sliskovic, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|April 1, 1994
ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundanceB R Krause, M E Pape, K Kieft, et al.
Life Sciences|May 16, 2000
Elevated hepatic apolipoprotein A-I transcription is associated with diet-induced hyperalphalipoproteinemia in rabbitsD A Schwab, T J Rea, J C Hanselman, et al.
Biochemical Pharmacology|March 15, 1995
Hepatic microsomal induction profile of carbamic acid [[2,6-bis(1- methylethyl)phenoxy] sulfonyl]-2,6-bis(1-methylethyl) phenyl ester, monosodium salt (PD138142-15), a novel lipid regulating agentD G Robertson, B R Krause, D F Welty, et al.
Atherosclerosis|June 28, 2001
The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regressionT M Bocan, B R Krause, W S Rosebury, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 2000
The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbitsT M Bocan, B R Krause, W S Rosebury, et al.
Journal of Lipid Research|February 1, 1993
In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACATB R Krause, M Anderson, C L Bisgaier, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1993
Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferaseB R Krause, A Black, R Bousley, et al.
Journal of Medicinal Chemistry|May 28, 1993
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 2. Modification of fatty acid anilide ACAT inhibitors: bioisosteric replacement of the amide bondW H Roark, B D Roth, A Holmes, et al.
Journal of Lipid Research|April 1, 1995
Tissue specific changes in acyl-CoA: cholesterol acyltransferase (ACAT) mRNA levels in rabbitsM E Pape, P A Schultz, T J Rea, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Biochemical and Biophysical Research Communications|July 31, 1990
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductaseM K Shaw, R S Newton, D R Sliskovic, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|April 1, 1994
ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet. Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundanceB R Krause, M E Pape, K Kieft, et al.
Life Sciences|May 16, 2000
Elevated hepatic apolipoprotein A-I transcription is associated with diet-induced hyperalphalipoproteinemia in rabbitsD A Schwab, T J Rea, J C Hanselman, et al.
Biochemical Pharmacology|March 15, 1995
Hepatic microsomal induction profile of carbamic acid [[2,6-bis(1- methylethyl)phenoxy] sulfonyl]-2,6-bis(1-methylethyl) phenyl ester, monosodium salt (PD138142-15), a novel lipid regulating agentD G Robertson, B R Krause, D F Welty, et al.
Atherosclerosis|June 28, 2001
The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regressionT M Bocan, B R Krause, W S Rosebury, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 2000
The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbitsT M Bocan, B R Krause, W S Rosebury, et al.
Journal of Lipid Research|February 1, 1993
In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACATB R Krause, M Anderson, C L Bisgaier, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1993
Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferaseB R Krause, A Black, R Bousley, et al.
Journal of Medicinal Chemistry|May 28, 1993
Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 2. Modification of fatty acid anilide ACAT inhibitors: bioisosteric replacement of the amide bondW H Roark, B D Roth, A Holmes, et al.
Journal of Lipid Research|April 1, 1995
Tissue specific changes in acyl-CoA: cholesterol acyltransferase (ACAT) mRNA levels in rabbitsM E Pape, P A Schultz, T J Rea, et al.
Pageof 6